Chimerix Inc share price today

(CMRX)

Chimerix Inc share price is $0.87 & ₹73.72 as on 5 Dec 2024, 2.30 'hrs' IST

$0.87

▲

0.01

(1.12%)

Market is closed - opens 8 PM, 05 Dec 2024

View live Chimerix Inc share price in Dollar and Rupees. Guide to invest in Chimerix Inc from India. Also see the sentimental analysis on Indian investors investing in Chimerix Inc. Get details on the Indian mutual funds that are investing in Chimerix Inc. Get Analyst recommendations and forecasts along with all the Chimerix Inc's financials.

Chimerix Inc share price movements

$0.84
$0.87
$0.87
3.28%
Downside
Day's Volatility :3.28%
Upside
0.0%
$0.75
$1.30
$0.87
13.79%
Downside
52 Weeks Volatility :42.31%
Upside
33.08%

Chimerix Inc Returns

Period	Chimerix Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	1.22%	-4.7%	0.0%
6 Months	-5.31%	0.9%	0.0%
1 Year	-8.27%	11.6%	0.0%
3 Years	-85.29%	12.9%	-18.1%

Chimerix Inc Key Statistics

in dollars & INR

Previous Close	$0.8603
Open	$0.85
Today's High	$0.87
Today's Low	$0.8415
Market Capitalization	$81.4M
Today's Volume	$243.7K
52 Week High	$1.3
52 Week Low	$0.75
Revenue TTM	$159.0K
EBITDA	$-92.7M
Earnings Per Share (EPS)	$-0.94
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-48.59%

How to invest in Chimerix Inc from India?

It is very easy for Indian residents to invest directly in Chimerix Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Chimerix Inc stock in both rupees (INR) and dollars (USD). Search for Chimerix Inc or CMRX on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Chimerix Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Chimerix Inc shares which would translate to 0.974 fractional shares of Chimerix Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Chimerix Inc

256%

Period: Sep 5, 2024 to Dec 4, 2024. Change in 30 Days versus previous period

Search volume for Chimerix Inc on INDmoney from India has grown in the last 30 days as on Dec 5, 2024. 256% more investors are searching Chimerix Inc in the last 30 days versus the previous period.

Global Institutional Holdings in Chimerix Inc

RA Capital Management, LLC
9.78%
Vanguard Group Inc
4.82%
Monaco Asset Management
4.69%
Millennium Management LLC
2.66%
Armistice Capital, LLC
2.46%
Vestal Point Capital LP
1.56%

Analyst Recommendation on Chimerix Inc

Buy

92%Buy

7%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Chimerix Inc(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Chimerix Inc

What analysts predicted

Upside of 704.6%

Current:

$0.87

Target:

$7.00

Insights on Chimerix Inc

Decreasing Revenue
Revenue is down for the last 2 quarters, 129.0K → 26.0K (in $), with an average decrease of 79.8% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -20.68M → -22.87M (in $), with an average decrease of 10.6% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 48.5% return, outperforming this stock by 56.0%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.6% return, outperforming this stock by 131.9%

Chimerix Inc Technicals Summary

Sell

Neutral

Buy

Chimerix Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Chimerix Inc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Chimerix Inc	-12.76%	-5.31%	-8.27%	-85.29%	-64.83%
Regeneron Pharmaceuticals, Inc.	-8.09%	-23.83%	-8.78%	21.97%	108.5%
Biontech Se	5.61%	15.12%	15.65%	-58.12%	304.14%
Alnylam Pharmaceuticals, Inc.	-4.63%	69.46%	44.56%	42.94%	109.6%
Vertex Pharmaceuticals Incorporated	-6.83%	-4.08%	31.76%	127.12%	112.3%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Chimerix Inc	0.48	NA	0.0	-1.0	-0.49	-0.3	NA	1.51
Regeneron Pharmaceuticals, Inc.	18.55	18.55	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.23	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Chimerix Inc	Buy	$81.4M	-64.83%	0.48	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$83.0B	108.5%	18.55	33.61%
Biontech Se	Buy	$28.9B	304.14%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	109.6%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$120.6B	112.3%	32.84	-4.51%

About Chimerix Inc

led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed

Organization	Chimerix Inc
Employees	72
CEO	Mr. Michael T. Andriole M.B.A.
Industry	Health Technology

Management People of Chimerix Inc

Name	Title
Mr. Michael T. Andriole M.B.A.	CEO, President & Director
Dr. Michael A. Alrutz J.D., Ph.D.	Senior VP, General Counsel & Corporate Secretary
Dr. Allen S. Melemed M.B.A., M.D.	Chief Medical Officer
Ms. Michelle LaSpaluto	Chief Financial Officer
Mr. Thomas J. Riga	Chief Operating & Commercial Officer
Mr. David Jakeman CPA	Vice President of Accounting & Finance
Dr. Joshua E. Allen Ph.D.	Chief Scientific Officer
Dr. Roy W. Ware M.B.A., Ph.D.	Chief Manufacturing Technology Officer

Important FAQs about investing in Chimerix Inc from India :

What is Chimerix Inc share price today?

Chimerix Inc (CMRX) share price today is $0.87.

Can Indians buy Chimerix Inc shares?

Yes, Indians can invest in the Chimerix Inc (CMRX) from India.

With INDmoney, you can buy Chimerix Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Chimerix Inc at zero transaction cost.

How can I buy Chimerix Inc shares from India?

It is very easy to buy Chimerix Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Chimerix Inc be purchased?

Yes, you can buy fractional shares of Chimerix Inc with INDmoney app.

What are the documents required to start investing in Chimerix Inc stocks?

To start investing in Chimerix Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.